Advanced Hepatocellular Carcinoma: Benefits of Atezolizumab and Bevacizumab in Clinical Practice. Case Report
DOI:
https://doi.org/10.22516/25007440.1304Keywords:
Hepatocellular Carcinoma, immunotherapy, tyrosine kinase inhibitorsAbstract
Background: Hepatocellular carcinoma (HCC), originating from hepatocytes, ranks as the sixth most common cancer worldwide and the fourth leading cause of cancer-related mortality. Treatment options include surgical resection, locoregional therapies, systemic therapy, and liver transplantation, depending on disease stage.
Case report: We describe a 78-year-old male with multiple comorbidities diagnosed with stage IIIB hepatocellular carcinoma according to the BCLC B classification. He was treated with atezolizumab and bevacizumab, achieving a favorable response with tumor marker negativization and stable disease.
Discussion: Since 2008, HCC treatment has undergone substantial progress. Earlier systemic therapies such as sorafenib and lenvatinib offered response rates around 24% and overall survival of up to 13 months. Current therapies have demonstrated significantly improved outcomes. Notably, the phase III IMbrave150 trial (2020) showed the advantages of combining immunotherapy with antiangiogenic agents over sorafenib in patients with advanced HCC, with overall survival reaching up to 89%.
Downloads
References
Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1-61. https://doi.org/10.1016/bs.acr.2020.10.001
Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589-604. https://doi.org/10.1038/s41575-019-0186-y
Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet (London). 2022;400(10360):1345-62. https://doi.org/10.1016/S0140-6736(22)01200-4
Ganesan P, Kulik LM. Hepatocellular Carcinoma: New Developments. Clin Liver Dis. 2023;27(1):85-102. https://doi.org/10.1016/j.cld.2022.08.004
Sim HW, Knox J. Hepatocellular carcinoma in the era of immunotherapy. Curr Probl Cancer. 2018;42(1):40-8. https://doi.org/10.1016/j.currproblcancer.2017.10.007
Finn RS, Ducreux M, Qin S, Galle PR, Zhu AX, Ikeda M, et al. IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma. J Clin Oncol 2018;36(15_suppl):TPS4141-TPS4141. https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS4141
Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, et al. Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: Patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2021;6(8):649-58.
Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, et al. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020;55(1):113-22. https://doi.org/10.1007/s00535-019-01642-1
Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862-73. https://doi.org/10.1016/j.jhep.2021.11.030
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Revista colombiana de Gastroenterología

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
Los autores/as ceden sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación en esta revista.
Los contenidos están protegidos bajo una licencia de Creative Commons Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional.

| Article metrics | |
|---|---|
| Abstract views | 639 |
| Galley views | 326 |
| PDF Views | 246 |
| HTML views | 0 |
| Other views | 80 |














